US-REGISTERED COMPANY
Skip to product information
Peptiva peptides
Research Compound Tirzepatide
€127,50
Sale price
€127,50
Regular price
€150,00
FOR IN VITRO LABORATORY RESEARCH ONLY.
Not intended for personal, clinical, diagnostic or veterinary use, or for administration to humans or animals.
Laboratory dispenser format
This description applies to the dispenser-format variant, not the vial-format variant.
The dispenser is a laboratory packaging and material-dispensing format. Product identity, declared quantity and storage conditions are stated in the specification for the individual material.
Laboratory dispensing format. It is not an injection or medical device and is not intended for administration to humans or animals.
MAIN RESEARCH AREAS Research profile
Editorial map of the main themes found in the scientific literature. Bar length is not a statistical score, efficacy rating, or indication for human use.
Description and specifications
Research Compound Tirzepatide is a laboratory material for analytical and in vitro work, available in 10 mg and 20 mg variants.
What is tirzepatide?
Tirzepatide is a synthetic 39-amino-acid peptide whose sequence is based on the hormone GIP, with an attached C20 fatty diacid chain. The molecular weight is approximately 4.8 kDa. Albumin binding extends the molecule's half-life.
Research background
Tirzepatide was developed by Eli Lilly as the first dual GIP and GLP-1 receptor agonist. Regulated pharmaceutical preparations containing tirzepatide are approved medicines with their own documentation, which does not apply to research materials.
Mechanism and scientific context
Tirzepatide activates the GIP and GLP-1 receptors and has been described in pharmacological studies as an “imbalanced” agonist with more pronounced activity at the GIP receptor. At the GLP-1 receptor it shows a bias towards cAMP signalling over β-arrestin recruitment, a subject of active receptor pharmacology research.
Main research areas
- GIP and GLP-1 receptors
- biased receptor signalling
- dual agonist pharmacology
- peptide binding to albumin
Level of evidence
A high level of clinical evidence exists for approved pharmaceutical preparations. This does not confirm the identity, purity or bioequivalence of this research material.
Related
See also Retatrutide and Semaglutide.
Research use only: for laboratory, analytical and in vitro research only; not for use in humans or animals. Not a medicine. Guidance on batch documentation is available in our COA guide.
PEPTIVA PRO E-BOOK · DIGITAL EDITION
Explore the scientific context in greater depth
The expanded guide covers more than 50 compounds, mechanisms of action, levels of evidence, limitations of the available data and research regimens reported in publicly available scientific literature.
- 50+ compounds covered in detail
- Preclinical and clinical data clearly distinguished
- Experimental approaches described in scientific literature
- COA, purity and documentation
Educational content is not medical advice, a recommendation for self-administration or instructions for using products sold in this store.
COA on request
To enquire about a certificate of analysis (COA), send the material name, requested variant and LOT / batch number if available. Documents are not published on this page.
Request a COA by emailThe button opens your email app with a prepared enquiry. You send the message yourself. peptivapeptides@protonmail.com
A COA applies to a specific batch and documents the analytical parameters tested for that batch. The product is intended strictly for laboratory, analytical and in vitro research.